NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAMS E-024-2018-0-IL-05 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING AND/OR PREVENTING PERIODONTAL DISEASE IL National Stage 274529 Pending
NCI E-133-2016-0-US-05 FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME US National Stage 16/304,552 11299546 Issued PDF
NIAID E-057-2011-2-US-05 VIRUS-LIKE PARTICLES AND METHODS OF USE US DIV 16/199,671 11098084 Issued PDF
NHLBI E-201-2016-0-EP-04 Annuloplasty Procedures, Related Devices And Methods EP National Stage 17793543.4 Pending
NHLBI E-149-2018-0-US-01 VDAC INHIBITORS FOR TREATING AUTOIMMUNE DISEASES US 62/771,211 Abandoned
NIEHS E-125-2018-1-US-01 Use of Epithelial Membrane Protein 2 (EMP2) Targeting Agents in Treating Lung Disorders US 62/771,326 Abandoned
NCI E-133-2016-0-JP-08 FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME JP National Stage 2018-561669 Pending
NHLBI E-218-2016-0-US-03 Immunogens, Compositions, And Methods For Treating Dyslipidemia US National Stage 16/304,020 Abandoned
NCI E-282-2016-2-NG-35 Methods For Pre-conditioning Patients For Cell Therapy NG DIV NG/PT/C/2018/3399 Abandoned
NIAID E-029-2007-0-US-04 RECOMBINANT VIRUS WITH DIMINISHED LATENCY AND METHODS OF USING SAME US DIV 16/195,247 11305009 Issued PDF
NIDDK E-064-2004-0-US-60 The Use Of Leptin For Treating Human Lipotrophy US CON 16/195,661 Abandoned
NEI E-015-2019-0-US-01 BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE US 62/769,484 Abandoned
NEI E-164-2018-2-US-01 NTRAOCULAR DELIVERY OF GENE THERAPY EXPRESSION VECTORS US 62/768,590 Abandoned
NIDCR E-026-2018-2-PCT-01 USE OF COPEPTIN TO MODULATE THE IMMUNE RESPONSE AND HEMATOPOIESIS, AND STIMULATE BONE GROWTH PCT PCT COMB PCT/US2018/061205 Expired
NIAID E-045-2015-0-US-05 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE US CON 16/190,676 10273288 Issued PDF
NCI E-007-2019-0-US-01 TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER US 62/767,230 Abandoned
NIBIB E-150-2016-0-EP-04 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP National Stage 17796666.0 Issued
NIBIB E-150-2016-0-DE-09 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents DE EP 17796666.0 Issued
NIBIB E-150-2016-0-FR-10 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents FR EP 17796666.0 Issued
NIBIB E-150-2016-0-GB-11 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents GB EP 17796666.0 Issued
NIBIB E-150-2016-0-CH-08 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents CH EP 17796666.0 Issued
NIBIB E-150-2016-0-IE-12 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents IE EP 17796666.0 Issued
NIBIB E-150-2016-0-IT-13 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents IT EP 17796666.0 Issued
NIDA E-005-2018-1-PCT-01 ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF PCT PCT COMB PCT/US2018/060260 Expired
NCI E-133-2016-0-AU-06 FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME AU National Stage 2017271606 Pending
NIBIB E-150-2016-0-CN-03 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents CN National Stage 201780029003X Issued
NIBIB E-150-2016-0-SG-07 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents SG National Stage 11201809982R Issued
NCATS E-036-2016-0-CN-05 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders CN National Stage 201780029039.8 Issued
NIBIB E-150-2016-0-JP-05 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents JP National Stage 2018-558662 Issued
NCI E-132-2017-0-PCT-02 METHODS OF PREPARING HEMATOPOIETIC PROGENITOR CELLS IN VITRO PCT PCT PCT/US2018/059856 Expired
NIAID E-099-2016-0-US-14 USE OF GRAM NEGATIVE SPECIES TO TREAT ATOPIC DERMATITIS US CON 16/184,498 Abandoned
NIAID E-139-2006-0-AU-66 Development Of Dengue Virus Vaccine Components AU DIV 2018260848 Issued
NIBIB E-150-2016-0-US-06 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS US National Stage 16/099,488 10696631 Issued PDF
NCI E-016-2018-0-PCT-02 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS PCT PCT PCT/US2018/059645 Expired
NCI E-016-2018-0-CN-03 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS CN National Stage 201880073043.9 Pending
NCI E-016-2018-0-HK-07 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS HK EP 62021026654.5 Pending
NCI E-016-2018-0-EP-04 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS EP National Stage 18822526.2 Pending
NCI E-016-2018-0-KR-05 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS KR National Stage 10-2020-7014565 Pending
NCI E-171-2018-8-US-04 INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY US CON 16/182,189 11642375 Issued PDF
NCI E-171-2018-8-US-03 MODIFIED CELLS AND METHODS OF THERAPY US CON 16/182,146 11642374 Issued PDF
NCI E-167-2017-0-CN-05 NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY CN National Stage 201880071646.5 Pending
NCI E-167-2017-0-JP-07 NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY JP National Stage 2020-524774 Pending
NCI E-167-2017-0-PCT-02 NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY PCT PCT PCT/US2018/059384 Expired
NCI E-167-2017-0-CA-04 NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY CA National Stage 3081757 Pending
NHLBI E-200-2018-0-US-01 NEW COMPOSITIONS AND METHODS FOR TREATING BETA-GLOBINOPATHIES US 62/756,497 Abandoned
NCI E-171-2018-8-US-02 MODIFIED CELLS AND METHODS OF THERAPY US CON 16/180,867 11903966 Issued PDF
NLM E-107-2010-2-US-25 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 16/180,450 10767216 Issued PDF
NCI E-038-2018-0-JP-07 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-ROR1 IMMUNOTHERAPY JP National Stage 2020-524450 Issued
NHLBI E-006-2014-0-US-13 MRI Compatible 3-D Inracardiac Echography Catheter And System US CON 16/178,665 11039811 Issued PDF
NHLBI E-156-2016-0-US-04 Derivation Of A Greater Than 25 Million-year-old Adeno-associated Virus Coat Protein Sequence US National Stage 16/098,810 10882886 Issued PDF